Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Beta in Primary IgA Nephropathy
NCT07888335Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 4 trial of obinutuzumab beta in IgA nephropathy (IgAN), sponsored by Ruijin Hospital. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
obinutuzumab beta
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07888335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888335.